Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Integrin-Linked Kinase a Novel Therapeutic Target for Acute and Chronic Myeloid Leukemia

Pilar De La Puente, PhD, Ellen Weisberg, MD, Atsushi Nonami, MDPhD, Micah John Luderer, BS, MS, Richard M. Stone, MD, Junia V. Melo, MD PhD, James D Griffin, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2015) 126 (23): 3694.

https://doi.org/10.1182/blood.V126.23.3694.3694

Published: 2015

Journal Articles

Transfusion Dependency Is Associated With Inferior Survival Even In Very Low and Low Risk IPSS-R Patients

Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Monika M Kutyna, Rakchha Chhetri, Stuart Howell, Peter B Harrison, Shriram V Nath, Lakshmi S Nath, Nicholas Wickham, Ferenc Szabo, Chi-Hung Hui, David Ross, James Gray, Junia V Melo, MD, PhD, Peter Bardy, L. Bik To

Blood (2013) 122 (21): 1518.

https://doi.org/10.1182/blood.V122.21.1518.1518

Published: 2013

Journal Articles

BCR-ABL-Induced Downregulation of GADD45G in Chronic Myeloid Leukemia

Debora A Casolari, PhD, Jun Ishiko, MD, PhD, Michelle Perugini, PhD, Richard J D'Andrea, PhD, Junia V Melo, MD, PhD

Blood (2012) 120 (21): 3731.

https://doi.org/10.1182/blood.V120.21.3731.3731

Published: 2012

Journal Articles

Socs2 Is Dispensable for BCR/ABL1-Induced Chronic Myeloid Leukemia-Like Disease in Mice and for Normal Hematopoietic Stem Cell Function,

Nils Hansen, Helena Agerstam, PhD, Martin Wahlestedt, Mats Ehinger, MD, PhD, Petra Johnels, PhD, Jun Ishiko, PhD, Junia V. Melo, MD, PhD, Warren S Alexander, PhD, David Bryder, Marcus Järås, PhD, Thoas Fioretos, MD, PhD

Blood (2011) 118 (21): 3743.

https://doi.org/10.1182/blood.V118.21.3743.3743

Published: 2011

Journal Articles

Mechanisms of Co-Operation of DNMT3A Mutations with JAK2 V617F Through Histone H4 Arginine 3 Provides New Insights in MPN Disease Pathogenesis

Nisha Rao, Carolyn M Butcher, MMedSc(Hon), Petra J Neufing, Sarah Bray, Chris N Hahn, Hamish S Scott, PhD, Junia V. Melo, MD, PhD, David Ross, MBBS, PhD, Ian D Lewis, MBBS, PhD, Peter Bardy, MD, Richard J D'Andrea, PhD

Blood (2011) 118 (21): 2823.

https://doi.org/10.1182/blood.V118.21.2823.2823

Published: 2011

Journal Articles

Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells.

Devendra K Hiwase, MD, Deborah L White, PhD, Jason A Powell, PhD, Verity A Saunders, Stephanie Zrim, Amity Frede, Mark Guthridge, Richard D'Andrea, PhD, L. Bik To, MD, Junia V. Melo, MD, PhD, Sharad Kumar, PhD, Timothy Hughes, MD

Blood (2009) 114 (22): 3250.

https://doi.org/10.1182/blood.V114.22.3250.3250

Published: 2009

Journal Articles

Targeting Isoprenylcysteine Carboxyl Methyltransferase to Overcome Resistance and Improve Responses in Chronic Myeloid Leukemia.

Wen Tian Sun, PhD, Bee Ling Ng, PhD, Li Yi Yang, BSc, Mei Wang, MD, PhD, William Hwang, MBBS, FRCP, Junia V. Melo, MD, PhD, Brian J. Druker, MD, Patrick J Casey, PhD, Charles Chuah, MBChB, MRCP, MD

Blood (2009) 114 (22): 3273.

https://doi.org/10.1182/blood.V114.22.3273.3273

Published: 2009

Journal Articles

A Gene Expression Signature of CD34+ Cells to Predict Major Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib: Potential Involvement of Beta-Catenin in Drug Resistance.

Shannon McWeeney, Gregory Yochum, Lucy C. Pemberton, MD, FRCPath, Marc Loriaux, MD, PhD, Kristina Vartanian, Stephanie G Willis, Beth Wilmot, Yaron Turpaz, Raji Pillai, Mary Mac partlin, Jennifer Snead, PhD, Brian J. Druker, MD, Stephen G O'Brien, MD, PhD, Junia V. Melo, MD, PhD, Thoralf Lange, MD, Christina Harrington, Michael Deininger, MD, PhD

Blood (2009) 114 (22): 508.

https://doi.org/10.1182/blood.V114.22.508.508

Published: 2009

Journal Articles

Bcr-Abl Positive Cells Display Increased Proteasome Activity and Greater Sensitivity to Proteasome Inhibition

Lisa Crawford, PhD, BSc, Philip Windrum, MD, MRCPath, Laura Magill, PhD, BSc, Junia V. Melo, MD, PhD, FRCPath, Lynn McCallum, PhD, BSc, MaryFrances McMullin, MD, Huib Ovaa, PhD, BSc, Brian Walker, PhD, BSc, Alexandra Irvine, PhD

Blood (2008) 112 (11): 3192.

https://doi.org/10.1182/blood.V112.11.3192.3192

Published: 2008

Journal Articles

Short –Term Intense Bcr-Abl Kinase Inhibition Is Adequate to Trigger Cell Death in CML Cell Lines but Not in CML-CD34+ Cells Unless They Are Growth Factor Deprived.

Devendra K. Hi Wase, MD, Deborah L. White, PhD, Verity A. Saunders, Junia V. Melo, MD, PhD, Sharad Kumar, PhD, Timothy P. Hughes, MD

Blood (2008) 112 (11): 1086.

https://doi.org/10.1182/blood.V112.11.1086.1086

Published: 2008

Journal Articles

Association between the Polycomb Group (PcG) BMI-1 Gene Expression and Outcome in Chronic Myeloid Leukemia (CML) Patients Receiving Allogeneic Stem Cell Transplantation (allo-SCT).

Mohamad Mohty, MD, PhD, Agnes S.M. Yong, MD, PhD, Richard M. Szydlo, PhD, Jane F. Apperley, MD, John M. Goldman, MD, Junia V. Melo, MD, PhD

Blood (2007) 110 (11): 464.

https://doi.org/10.1182/blood.V110.11.464.464

Published: 2007

Journal Articles

How Cured Are CML Patients in Complete Molecular Remission (CMR) after Stem Cell Transplantation or Imatinib?.

Manuel S. Simoes, MD, Joannah Score, Nicholas C.P. Cross, PhD, Jane F. Apperley, MD, Junia V. Melo, MD, PhD

Blood (2007) 110 (11): 1009.

https://doi.org/10.1182/blood.V110.11.1009.1009

Published: 2007

Journal Articles

BMS-214662 Eliminates CML Stem Cells and Is Active Against Blast Crisis CML and Cells Expressing BCR-ABL Kinase Mutations.

Mhairi Copland, MD, Linda Richmond, BSc, Ashley Hamilton, BSc, Elaine K. Allan, BSc, Junia V. Melo, MD, PhD, Tessa L. Holyoake, MD, PhD

Blood (2006) 108 (11): 739.

https://doi.org/10.1182/blood.V108.11.739.739

Published: 2006

Journal Articles

Transcriptional Regulation of the Bach2 B-Cell Differentiation and Apoptotic Factor by the Bcr-Abl Oncoprotein.

Maria Makri, BSc, Chikashi Yoshida, MD, PhD, Akihiko Muto, PhD, Kazuhiko Igarashi, MD, PhD, Junia V Melo, MD, PhD

Blood (2005) 106 (11): 2991.

https://doi.org/10.1182/blood.V106.11.2991.2991

Published: 2005

Journal Articles

Selective Inhibition of Lysophosphatidic Acid Acyltransferase-β by CT32228 Inhibits MAPK and Enhances the Antileukemic Activity of Imatinib in BCR-ABL Expressing Cell Lines Resistant to Imatinib.

Paul La Rosée, MD, Taiping Jia, BS, Shadmehr Demehri, Peter de Vries, PhD, Lynn Bonham, PhD, Junia V. Melo, MD, PhD, Jack W. Singer, MD, PhD, Brian J. Druker, MD, Michael W. Deininger, MD, PhD

Blood (2005) 106 (11): 1524.

https://doi.org/10.1182/blood.V106.11.1524.1524

Published: 2005

Journal Articles

Molecular Profiling of CD34+ Cells from Diagnosis in CML Patients Identifies Low Expression of CD7 with High Expression of Proteinase 3 or Elastase as Predictors of Longer Survival.

Agnes S.M. Yong, MD, PhD, Richard M. Szydlo, PhD, John M. Goldman, MD, Jane F. Apperley, MD, Junia V. Melo, MD, PhD

Blood (2005) 106 (11): 1984.

https://doi.org/10.1182/blood.V106.11.1984.1984

Published: 2005

Journal Articles

Glutathione-Depletion Potently Enhances the Cytotoxic Activity of Arsenic Trioxide in Imatinib Sensitive and Resistant Bcr-Abl Positive Cell Lines.

Heiko Koenig, MD, Erika M. Moseson, MA, Christian Lorentz, MD, Peter Paschka, MD, Junia V. Melo, MD, PhD, Ruediger Hehlmann, MD, Andreas Hochhaus, MD, Paul La Rosée, MD

Blood (2004) 104 (11): 2098.

https://doi.org/10.1182/blood.V104.11.2098.2098

Published: 2004

Journal Articles

The Proteome Analysis of an Imatinib-Resistant Cell Line Identifies Changes in Molecular Chaperones Such as Heat Shock Proteins (Hsp): A Possible New Mechanism of Imatinib Resistance.

Jean-Max Pasquet, PhD, Marion Pocaly, Valérie Lagarde, Béatrice Turcq, PhD, Josy Reiffers, MD, Junia V. Melo, MD PhD, Francois-Xavier Mahon, MD PhD

Blood (2004) 104 (11): 1981.

https://doi.org/10.1182/blood.V104.11.1981.1981

Published: 2004

NARROW

Integrin-Linked Kinase a Novel Therapeutic Target for Acute and Chronic Myeloid Leukemia

Transfusion Dependency Is Associated With Inferior Survival Even In Very Low and Low Risk IPSS-R Patients

BCR-ABL-Induced Downregulation of GADD45G in Chronic Myeloid Leukemia

Socs2 Is Dispensable for BCR/ABL1-Induced Chronic Myeloid Leukemia-Like Disease in Mice and for Normal Hematopoietic Stem Cell Function,

Mechanisms of Co-Operation of DNMT3A Mutations with JAK2 V617F Through Histone H4 Arginine 3 Provides New Insights in MPN Disease Pathogenesis

Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells.

Targeting Isoprenylcysteine Carboxyl Methyltransferase to Overcome Resistance and Improve Responses in Chronic Myeloid Leukemia.

A Gene Expression Signature of CD34+ Cells to Predict Major Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib: Potential Involvement of Beta-Catenin in Drug Resistance.

Bcr-Abl Positive Cells Display Increased Proteasome Activity and Greater Sensitivity to Proteasome Inhibition

Short –Term Intense Bcr-Abl Kinase Inhibition Is Adequate to Trigger Cell Death in CML Cell Lines but Not in CML-CD34+ Cells Unless They Are Growth Factor Deprived.

Association between the Polycomb Group (PcG) BMI-1 Gene Expression and Outcome in Chronic Myeloid Leukemia (CML) Patients Receiving Allogeneic Stem Cell Transplantation (allo-SCT).

How Cured Are CML Patients in Complete Molecular Remission (CMR) after Stem Cell Transplantation or Imatinib?.

BMS-214662 Eliminates CML Stem Cells and Is Active Against Blast Crisis CML and Cells Expressing BCR-ABL Kinase Mutations.

Transcriptional Regulation of the Bach2 B-Cell Differentiation and Apoptotic Factor by the Bcr-Abl Oncoprotein.

Selective Inhibition of Lysophosphatidic Acid Acyltransferase-β by CT32228 Inhibits MAPK and Enhances the Antileukemic Activity of Imatinib in BCR-ABL Expressing Cell Lines Resistant to Imatinib.

Molecular Profiling of CD34+ Cells from Diagnosis in CML Patients Identifies Low Expression of CD7 with High Expression of Proteinase 3 or Elastase as Predictors of Longer Survival.

Glutathione-Depletion Potently Enhances the Cytotoxic Activity of Arsenic Trioxide in Imatinib Sensitive and Resistant Bcr-Abl Positive Cell Lines.

The Proteome Analysis of an Imatinib-Resistant Cell Line Identifies Changes in Molecular Chaperones Such as Heat Shock Proteins (Hsp): A Possible New Mechanism of Imatinib Resistance.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only